Expert Interview
A Look at the Recent FDA Approval of Rhythm Pharmaceuticals' IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Ticker(s): RYTM, LLY, NVOInstitution: Vanderbilt University
- Assistant Professor of Pediatrics in the Division of Endocrinology and Diabetes at Vanderbilt University Medical Center with advanced training in clinical research.
- Manages 50 patients with Hypothalmic Obesity and 100 patients with PWS
- Involved in cutting edge clinical trials for patients with Prader-Willi syndrome, pseudohypoparathyroidism, hypothalamic obesity and disorders of the melanocortin 4 pathway.
How are you currently managing patients with acquired hypothalamic obesity, and what unmet needs remain with existing treatment approaches?
Added By: sara_adminWhat is your interpretation of the Phase 3 TRANSCEND data for setmelanotide, particularly the magnitude and clinical relevance of weight loss observed?
Added By: sara_adminWhich patient populations with hypothalamic obesity do you believe are most appropriate candidates for IMCIVREE®, and how would you approach patient selection?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
